A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria

Journal of Allergy and Clinical Immunology

Volumn 128, Issue 3, 2011, Pages

  Saini, Sarbjit ^a   Rosen, Karin E ^b   Hsieh, Hsin Ju ^b   Wong, Dennis A ^b   Conner, Edward ^b   Kaplan, Allen ^c   Spector, Sheldon ^d   Maurer, Marcus ^e  

^a JOHNS HOPKINS ASTHMA AND ALLERGY CENTER   (United States)

^b GENENTECH INC   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Chronic idiopathic urticaria; chronic spontaneous urticaria; dose ranging; hive; itch; omalizumab; urticaria activity score

Indexed keywords

CETIRIZINE; DESLORATADINE; FEXOFENADINE; HISTAMINE H1 RECEPTOR ANTAGONIST; LEVOCETIRIZINE; LORATADINE; OMALIZUMAB; PLACEBO;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CHRONIC IDIOPATHIC URTICARIA; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GERMANY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SINGLE DRUG DOSE; TREATMENT DURATION; TREATMENT OUTCOME; UNITED STATES; URTICARIA;

EID: 80052299857     PISSN: 00916749     EISSN: 10976825     Source Type: Journal    
DOI: 10.1016/j.jaci.2011.06.010     Document Type: Article

References (29)

1. T. Zuberbier, R. Asero, C. Bindslev-Jensen, C.G. Walter, M.K. Church, and A. Gimenez-Arnau EAACI/GA(2)LEN/EDF/WAO guideline: definition, classification and diagnosis of urticaria Allergy 64 2009 1417 1426
2. M.W. Greaves Chronic idiopathic urticaria Curr Opin Allergy Clin Immunol 3 2003 363 368 (Pubitemid 37254717)
3. P. Staubach, A. Eckhardt-Henn, M. Dechene, A. Vonend, M. Metz, and M. Magerl Quality of life in patients with chronic urticaria is differentially impaired and determined by psychiatric comorbidity Br J Dermatol 154 2006 294 298 (Pubitemid 43382700)
4. B.F. O'Donnell, F. Lawlor, J. Simpson, M. Morgan, and M.W. Greaves The impact of chronic urticaria on the quality of life Br J Dermatol 136 1997 197 201 (Pubitemid 27062719)
5. R.A. Sabroe, E. Fiebiger, D.M. Francis, D. Maurer, P.T. Seed, and C.E. Grattan Classification of anti-FcepsilonRI and anti-IgE autoantibodies in chronic idiopathic urticaria and correlation with disease severity J Allergy Clin Immunol 110 2002 492 499
6. M. Hide, D.M. Francis, C.E. Grattan, J. Hakimi, J.P. Kochan, and M.W. Greaves Autoantibodies against the high-affinity IgE receptor as a cause of histamine release in chronic urticaria N Engl J Med 328 1993 1599 1604 (Pubitemid 23151920)
7. A.P. Kaplan, and M. Greaves Pathogenesis of chronic urticaria Clin Exp Allergy 39 2009 777 787
8. J.A. Eckman, P.M. Sterba, L. Gober, R.G. Hamilton, and S.S. Saini Immunoenzymetric assay measurement (IEMA) of autoantibodies in chronic idiopathic urticaria (CIU) in relation to basophil functional profile over time J Allergy Clin Immunol 121 suppl 2008 S100
9. J.A. Eckman, R.G. Hamilton, and S.S. Saini Independent evaluation of a commercial test for "autoimmune" urticaria in normal and chronic urticaria subjects J Invest Dermatol 129 2009 1584 1586
10. L.A. Brodell, L.A. Beck, and S.S. Saini Pathophysiology of chronic urticaria Ann Allergy Asthma Immunol 100 2008 291 298 (Pubitemid 351520318)
11. T. Zuberbier, R. Asero, C. Bindslev-Jensen, C.G. Walter, M.K. Church, and A.M. Gimenez-Arnau EAACI/GA(2)LEN/EDF/WAO guideline: management of urticaria Allergy 64 2009 1427 1443
12. M. Staevska, T.A. Popov, T. Kralimarkova, C. Lazarova, S. Kraeva, and D. Popova The effectiveness of levocetirizine and desloratadine in up to 4 times conventional doses in difficult-to-treat urticaria J Allergy Clin Immunol 125 2010 676 682
13. C.E. Grattan, B.F. O'Donnell, D.M. Francis, N. Niimi, R.J. Barlow, and P.T. Seed Randomized double-blind study of cyclosporin in chronic "idiopathic" urticaria Br J Dermatol 143 2000 365 372 (Pubitemid 30650407)
14. Xolair [prescribing information] 2010 Genentech, Inc South San Francisco (CA)
15. Xolair: summary of product characteristics. European Medicines Agency; 2010. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR--- Product-Information/human/000606/WC500057298.pdf. Accessed June 23, 2011.
16. D.W. MacGlashan Jr., B.S. Bochner, D.C. Adelman, P.M. Jardieu, A. Togias, and J. Kenzie-White Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody J Immunol 158 1997 1438 1445 (Pubitemid 127469971)
17. L.A. Beck, G.V. Marcotte, D. MacGlashan, A. Togias, and S. Saini Omalizumab-induced reductions in mast cell FcepsilonRI expression and function J Allergy Clin Immunol 114 2004 527 530 (Pubitemid 39194924)
18. J.M. Oliver, C.A. Tarleton, L. Gilmartin, T. Archibeque, C.R. Qualls, and L. Diehl Reduced FcepsilonRI-mediated release of asthma-promoting cytokines and chemokines from human basophils during omalizumab therapy Int Arch Allergy Immunol 151 2009 275 284
19. S.L. Spector, and R.A. Tan Effect of omalizumab on patients with chronic urticaria Ann Allergy Asthma Immunol 99 2007 190 193 (Pubitemid 47264781)
20. S.L. Spector, and R.A. Tan Therapeutic alternatives for chronic urticaria: additional reports on omalizumab Ann Allergy Asthma Immunol 101 2008 647
21. A.P. Kaplan, K. Joseph, R.J. Maykut, G.P. Geba, and R.K. Zeldin Treatment of chronic autoimmune urticaria with omalizumab J Allergy Clin Immunol 122 2008 569 573
22. L.M. Gober, P.M. Sterba, J.A. Eckman, and S.S. Saini Effect of Anti-IgE (omalizumab) in chronic idiopathic urticaria (CIU) patients J Allergy Clin Immunol 121 suppl 2008 S147
23. M. Magerl, P. Staubach, S. Altrichter, E. Ardelean, K. Krause, and M. Metz Effective treatment of therapy-resistant chronic spontaneous urticaria with omalizumab J Allergy Clin Immunol 126 2010 665 666
24. M. Metz, S. Altrichter, E. Ardelean, B. Kebetaler, K. Krause, and M. Magerl Anti-immunoglobulin E treatment of patients with recalcitrant physical urticaria Int Arch Allergy Immunol 154 2010 177 180
25. T. Zuberbier, C. Bindslev-Jensen, W. Canonica, C.E. Grattan, M.W. Greaves, and B.M. Henz EAACI/GA2LEN/EDF guideline: definition, classification and diagnosis of urticaria Allergy 61 2006 316 320 (Pubitemid 43381808)
26. A. Mlynek, A. Zalewska-Janowska, P. Martus, P. Staubach, T. Zuberbier, and M. Maurer How to assess disease activity in patients with chronic urticaria? Allergy 63 2008 777 780 (Pubitemid 351591864)
27. S.D. Mathias, S.C. Dreskin, A. Kaplan, S.S. Saini, S. Spector, and K.E. Rosen Development of a daily diary for patients with chronic idiopathic urticaria Ann Allergy Asthma Immunol 105 2010 142 148
28. S. Holgate, R. Buhl, J. Bousquet, N. Smith, Z. Panahloo, and P. Jimenez The use of omalizumab in the treatment of severe allergic asthma: a clinical experience update Respir Med 103 2009 1098 1113
29. M. Maurer Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyreoperoxidase J Allergy Clin Immunol 2011 [Epub ahead of print]